PreComb
PreComb is a Swiss biotech company specializing in proprietary 3DTwin® technology that enables evidence-based, personalized cancer treatment decisions. Their platform uses patient-derived 3D tumor models combined with automated drug screening and AI-guided data analysis to improve precision oncology. The technology supports researchers, pharmaceutical companies, and oncologists by providing clinically relevant drug testing that accelerates drug discovery, reduces costs, and aims to improve patient outcomes. Founded in 2018 by serial biotech entrepreneurs with extensive expertise, PreComb is positioned to advance personalized oncology through innovative 3D cell culture and lab automation technologies, currently focusing on research and development with plans for future clinical application.
PreComb
PreComb is a Swiss biotech company specializing in proprietary 3DTwin® technology that enables evidence-based, personalized cancer treatment decisions. Their platform uses patient-derived 3D tumor models combined with automated drug screening and AI-guided data analysis to improve precision oncology. The technology supports researchers, pharmaceutical companies, and oncologists by providing clinically relevant drug testing that accelerates drug discovery, reduces costs, and aims to improve patient outcomes. Founded in 2018 by serial biotech entrepreneurs with extensive expertise, PreComb is positioned to advance personalized oncology through innovative 3D cell culture and lab automation technologies, currently focusing on research and development with plans for future clinical application.